Sage Journals: Discover world-class research

Abstract

Objective

To identify the dominant clinical factors associated with increased 1-year charges in treating head and neck cancer.

Study Design

Retrospective review.

Setting

Single academic institution.

Subjects and Methods

We retrospectively reviewed 1-year charges for 196 consecutive patients with head and neck cancer (HNC) who were treated exclusively at our institution. We analyzed charges by department as well as factors associated with increased charges per multivariable regression.

Results

The mean age was 59.6 years (SD, 14.9). Most of the population was male (64%), white (70%), and commercially insured (46%). The most common primary sites were the oropharynx (25%; 76%, HPV positive), skin (19%), and thyroid (17%). Eighty-three percent of total charges were due to standard-of-care treatment for HNC: surgery ($16 million), radiation therapy ($22 million), or chemotherapy ($11 million). The median total charge per patient was $212,484 (interquartile range, $78,630-$475,823). Multivariable regression demonstrated that the following were associated with increased charges: nasopharynx subsite ($250,929 [95% CI, $93,290-$408,569]; effect size in US dollars, P = .002), advanced stage (American Joint Committee on Cancer, seventh edition; $80,331 [$22,726-$137,936], P = .007), therapeutic surgery ($281,893 [$117,371-$446,415], P = .001), chemotherapy ($183,331 [$125,497-$241,165], P < .001), radiation ($203,397 [$143,454-$263,341], P < .001), surgical complication requiring return to the operating room ($147,247 [$37,240-$257,254], P = .009), emergency department visits ($89,050 [$23,811-$154,289], P = .008), and admissions ($140,894 [$82,895-$198,893], P < .001; constant, –$233,927 [–$410,790 to –$57,064]). The top quartile accrued 55% of the total charges.

Conclusion

Radiation, followed by surgery and chemotherapy, were the most expensive components of HNC care. In this analysis, we identified the dominant clinical factors associated with increased charges.

Keywords

costs charges head and neck cancer radiation surgery chemotherapy palliative curative

Get full access to this article

View all access options for this article.

References

Kale

Carroll

NV.

Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer. 2016;122(8):283-289.

Bach

PB.

Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6):626-633.

Zafar

Peppercorn

Schrag

, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18(4):381-390.

Young

RC.

Value-based cancer care. N Engl J Med. 2015;373(27):2593-2595.

Mariotto

Yabroff

Shao

Feuer

Brown

ML.

Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-128.

Banegas

Guy

Jr de Moor

, et al. For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff (Millwood). 2016;35(1):54-61.

Massa

Osazuwa-Peters

Adjei Boakye

Walker

Ward

GM.

Comparison of the financial burden of survivors of head and neck cancer with other cancer survivors. JAMA Otolaryngol Head Neck Surg. 2019;145(3):239-249.

Chang

Yin

Wei

, et al. Adjusted age-adjusted Charlson Comorbidity Index score as a risk measure of perioperative mortality before cancer surgery. PLoS One. 2016;11(2):e0148076.

Charlson

Szatrowski

Peterson

Gold

Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-1251.

10.

Nilsen

Johnson

JT.

Potential for low-value palliative care of patients with recurrent head and neck cancer. Lancet Oncol. 2017;18(5):e284-e289.

11.

Tam

Orosco

Dimitrios Colevas

, et al. Cost comparison of treatment for oropharyngeal carcinoma. Laryngoscope. 2019;129(7):1604-1609.

12.

Warren

Yabroff

Meekins

Topor

Lamont

Brown

ML.

Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100(12):888-897.

13.

Sirintrapun

Lopez

AM.

Telemedicine in cancer care. Am Soc Clin Oncol Educ Book. 2018;38:540-545.

14.

Leung

CYW

Cheung

Charbonneau

Prica

Chan

KKW

. Financial impact of cancer drug wastage and potential cost savings from mitigation strategies. J Oncol Pract. 2017;13(7):e646-e652.

15.

May

Garrido

Cassel

, et al. Cost analysis of a prospective multi-site cohort study of palliative care consultation teams for adults with advanced cancer: where do cost-savings come from? Palliat Med. 2017;31(4):378-386.

16.

Park

Poku

Taylor

Makary

MA.

Variation in markups on outpatient oncology services in the United States. Am J Manag Care. 2018;24(2):e59-e60.

17.

Giacomino

Cram

Vaughan-Sarrazin

Zhou

Girotra

Association of hospital prices for coronary artery bypass grafting with hospital quality and reimbursement. Am J Cardiol. 2016;117(7):1101-1106.

18.

Haidar

Tripathi

Tjoa

, et al. Antibiotic prophylaxis in clean-contaminated head and neck cases with microvascular free flap reconstruction: a systematic review and meta-analysis. Head Neck. 2018;40(2):417-427.

19.

Dort

Farwell

Findlay

, et al. Optimal perioperative care in major head and neck cancer surgery with free flap reconstruction: a consensus review and recommendations from the enhanced recovery after surgery society. JAMA Otolaryngol Head Neck Surg. 2017;143(3):292-303.

20.

Public Policy Institute of California, McConville

Danielson

Hsia

Emergency department use in California—demographics, trends, and the impact of the ACA. https://www.ppic.org/publication/emergency-department-use-in-california-demographics-trends-and-the-impact-of-the-aca/. Published 2019. Accessed August 12, 2019.

21.

Institute of Medicine. Hospital-Based Emergency Care: At the Breaking Point. Washington, DC: The National Academies Press; 2007.

22.

Kansagara

Englander

Salanitro

, et al. Risk prediction models for hospital readmission: a systematic review. JAMA. 2011;306(15):1688-1698.

23.

Coleman

Min

Chomiak

Kramer

AM.

Posthospital care transitions: patterns, complications, and risk identification. Health Serv Res. 2004;39(5):1449-1465.

24.

Wadhera

Joynt Maddox

Wasfy

Haneuse

Shen

Yeh

RW.

Association of the hospital readmissions reduction program with mortality among medicare beneficiaries hospitalized for heart failure, acute myocardial infarction, and pneumonia. JAMA. 2018;320(24):2542-2552.

25.

Medicare Payment Advisory Commission. Report to the Congress: Medicare and the Health Care Delivery System. Washington, DC: Medicare Payment Advisory Commission; 2018.

26.

van Walraven

Bennett

Jennings

Austin

Forster

AJ.

Proportion of hospital readmissions deemed avoidable: a systematic review. CMAJ. 2011;183(7):E391-E402.

27.

Borsuk

Al-Khamis

Geiser

, et al. S128: active post discharge surveillance program as a part of Enhanced Recovery After Surgery protocol decreases emergency department visits and readmissions in colorectal patients. Surg Endosc. 2019;33(11):3816-3827.

28.

Cohen

EEW

Soulieres

Le Tourneau

, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156-167.

29.

Ferris

Blumenschein

Jr Fayette

, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-1867.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB